Evolus (EOLS) Misses Q1 EPS by 21c, Misses on Revenue; Offers FY25 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. HUM
8. CSCO
9. KTOS
10. NVDA

Go back to Evolus (EOLS) Misses Q1 EPS by 21c, Misses on Revenue; Offers FY25 Revenue Guidance

Evolus Reports First Quarter 2025 Results

May 7, 2025 4:05 PM EDT

Global Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Achieving Positive Non-GAAP Operating Income on a Consolidated Basis for the Full-Year 2025 Evolysse Launched in Q2 and Off to a Strong Start Reaffirms 2025 Net Revenue Guidance of $345 Million to $355 Million; Evolysse and Estyme® Injectable Hyaluronic Acid (HA) Gels Anticipated to Contribute 8 to 10% of Total Revenue for the Full-Year... More